15 Sep 2016 07:00
Tiziana Life Sciences PLC
("Tiziana" or the "Company")
Confirmation of Capital Reduction
London, 15 September 2016 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, today announces, further to its announcement dated 30 June 2016 the High Court made an Order on 14 September 2016 ("Order") confirming the capital reduction approved by shareholders pursuant to Resolution 9 passed at the Annual General Meeting ("AGM").
The Order has been registered at Companies House. Details of the capital reduction were set out in the Notice of AGM dated 7 June 2016 and the proposal was approved by shareholders at the AGM held on 30 June 2016.
Contacts:
Tiziana Life Sciences plc | +44 (0)20 7493 2853 |
Gabriele Cerrone, Chairman and founder | |
Cairn Financial Advisers LLP | +44 (0)20 7148 7900 |
(Nominated adviser) | |
Liam Murray | |
Beaufort Securities Limited | +44 (0)20 7382 8300 |
(Broker) | |
Saif Janjua | |
FTI Consulting | +44 (0)20 3727 1000 |
Simon Conway / Natalie Garland-Collins |
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology.
The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently completing phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy and has filed an IND to enroll patients in an exploratory trial in hepatic cellular carcinoma (HCC).
The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
Tiziana Life Sciences' clinical development teams are working on its Bcl-3 candidate, which has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility and has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease. The Company is preparing the IND package with the intention of progressing to clinical trials early 2017.
For more information go to http://www.tizianalifesciences.com